Encoded Therapeutics
Home
Our Science
⟵
⟵ Back
Overview
Genetic Medicines Product Engine
Pipeline & Programs
⟵
⟵ Back
Overview
Pipeline
Clinical Studies
ETX101 for Dravet Syndrome
Research Areas
Publications & Presentations
Patient
Community
⟵
⟵ Back
Overview
Patient Community Stories
Dravet Syndrome
Pre-Approval Access Statement
Healthcare
Professionals
About
News
⟵
⟵ Back
Overview
Press Releases
Media Kit
Careers
Contact
Encoded Therapeutics
News
Careers
Contact
Home
Our Science
Overview
Genetic Medicines Product Engine
Pipeline &
Programs
Overview
Pipeline
Clinical Studies
ETX101 for Dravet Syndrome
Research Areas
Publications & Presentations
Patient
Community
Overview
Patient Community Stories
Dravet Syndrome
Pre-Approval Access Statement
Healthcare
Professionals
About
Overview
Leadership
Board of Directors
Investors
ETX201: An AAV9-based Vectorized miRNA Therapeutic Candidate for Angelman Syndrome
Post navigation
Previous:
Potent and Specific AAV9-miRNA Candidates Demonstrate Robust Reduction of Microtubule-associated Protein Tau (
MAPT
) in Non-Human Primates
Next:
Challenges and lessons learned in designing first-in-human trials of genetic therapies
